Key result
High-throughput sequencing links ~13,000 differentially expressed circulating circRNAs to late recurrence in PAF.
Why the study?
Late recurrence of paroxysmal atrial fibrillation post-PVI is common with elusive mechanisms, and peripheral blood circRNA expression patterns and regulatory functions in LRAF are unclear.
What is the circulating circRNA expression profile associated with late recurrence of paroxysmal atrial fibrillation post catheter ablation?
Case-Control (n=6)
What is the circulating circRNA expression profile associated with late recurrence of paroxysmal atrial fibrillation post catheter ablation?
Specific circulating circRNAs are differentially expressed in patients with late recurrence of paroxysmal atrial fibrillation after catheter ablation, suggesting potential roles as risk markers or therapeutic targets.
Circulating circRNA profiles may inform late PAF recurrence risk stratification; hypothesis-generating and requires prospective validation before clinical adoption.
BACKGROUND: Catheter-based pulmonary vein isolation (PVI) is an effective and well-established intervention for symptomatic paroxysmal atrial fibrillation (PAF). Nevertheless, late recurrences of atrial fibrillation (LRAF) occurring during 3 to 12 months are common, and the underlying mechanisms remain elusive. Circular RNAs (circRNAs) in atrial tissue have been linked to the pathophysiological mechanisms and progression of PAF in a few studies. However, their expression patterns in peripheral blood and regulatory function in LRAF are not clear. METHODS: In the present study, the expression profile of circulating circRNAs in three paired nonvalvular PAF patients with or without LRAF was investigated by high-throughput sequencing and validated by quantitative real-time polymerase chain reaction (qRT-PCR). Bioinformatics analyses, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and circRNA/miRNA regulatory network, were performed to predict the functions and potential regulatory roles of differentially expressed (DE) circRNAs. RESULTS: A total of 12,834 circRNAs, comprising 5,491 down-regulated and 7,343 up-regulated circRNAs, were found to be DE in blood smaples from the two groups in peripheral blood between LRAF and non-recurrence control individuals. The most enriched GO categories in terms of molecular function, biological process, and cellular component features were catalytic activity, cellular metabolic process, and intracellular part, respectively. The KEGG enrichment study revealed that the most important metabolic process controlled by DE circRNAs is endocytosis. In the circRNA/microRNAs interaction network, four up-regulated circRNAs (hsa_circ_0002665, hsa_circ_0001953, hsa_circ_0003831, and hsa_circ_0040533) and one down-regulated circRNA (hsa_circ_0041103) were predicted to play potential regulatory roles in the pathogenesis of LRAF. CONCLUSIONS: This investigation discovered the expression pattern of circulating circRNAs that is indicative of PAF late recurrence, which may serve as risk markers or therapeutic targets for LRAF after PVI.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2023) conducted a case-control in Paroxysmal atrial fibrillation (PAF) (n=6). Late recurrence of atrial fibrillation (LRAF) vs. No late recurrence was evaluated on Differentially expressed circulating circRNAs. High-throughput sequencing identified 12,834 differentially expressed circulating circRNAs (5,491 down-regulated and 7,343 up-regulated) between PAF patients with and without late recurrence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: